Form 4: Stepan VP & GM Moriarty Boosts Stake with Equity Grants

Stepan Co.'s VP & GM of Surfactants, Sean Thomas Moriarty, increased his beneficial ownership through stock acquisition and significant equity grants.

Summary

• Sean Thomas Moriarty, VP & GM Surfactants at Stepan Co. (SCL), reported an increase in his beneficial ownership.
• Acquired 56.765 shares of Common Stock at a price of $52.51 per share on February 27, 2026.
• Received a grant of 7,155 Stock Appreciation Rights (SARs) on March 2, 2026, with an exercise price of $17.47, vesting ratably over three years starting March 2, 2027, and expiring March 3, 2036.
• Received a grant of 4,495 Restricted Stock Units (RSUs) on March 2, 2026, vesting ratably over three years starting March 2, 2027, and expiring March 2, 2029. Each RSU represents a contingent right to receive one share of common stock.
• Received a grant of 2,247 Performance Shares on March 2, 2026, which vest upon the company achieving certain performance goals for the period ending December 31, 2028. Each performance share represents a contingent right to receive one share of common stock.
• Following these transactions, Moriarty beneficially owns 14,205.2335 shares directly and 4,478.351 shares indirectly through the ESOP II Trust.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive signal, as increased insider ownership and performance-linked equity grants typically indicate management's confidence in the company's future prospects and a commitment to long-term value creation.

Positives

• Sean Thomas Moriarty acquired 56.765 shares of Common Stock, increasing his direct ownership.
• Significant equity grants (SARs, RSUs, Performance Shares) align management's interests with shareholder value creation.
• The grants are performance-based (Performance Shares) or time-vested (SARs, RSUs), indicating a long-term commitment.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to senior management, such as those reported by Stepan Co., are a common practice across the specialty chemicals industry. These grants serve to incentivize long-term performance and align executive compensation with shareholder interests, particularly in sectors requiring sustained R&D and market development.

Comparison to Industry Standards

• The structure of equity compensation, including a mix of direct stock purchases, Stock Appreciation Rights, Restricted Stock Units, and performance-based shares, is consistent with best practices observed in peer companies within the specialty chemicals sector, such as Albemarle Corporation or Ecolab Inc.
• These companies often use similar long-term incentive plans to retain talent and drive strategic objectives.
• The vesting schedules and performance conditions are typical for executive compensation packages designed to foster multi-year commitment and achievement of specific financial or operational targets.

Related Party Transactions

• Indirect beneficial ownership of 4,478.351 shares through the ESOP II Trust, which is a standard employee benefit arrangement.

Stakeholder Impact

• Shareholders: Increased confidence due to insider buying and alignment of management incentives with shareholder interests.
• Employees: The ESOP II Trust indicates an employee stock ownership plan, which can foster a sense of ownership among employees.
• Management: Enhanced motivation through performance-based compensation and increased personal stake in the company's success.

Key Dates

Recommendation

The insider's direct purchase of shares, coupled with substantial equity grants tied to future performance, signals strong management confidence in Stepan Co.'s outlook. This alignment of interests, particularly with performance-based vesting, suggests a positive long-term trajectory for the stock, making it an attractive 'buy' for investors.

Keywords

Stepan Co., SCL, Form 4, Insider Transaction, Sean Thomas Moriarty, Stock Appreciation Rights, Restricted Stock Units, Performance Shares, Equity Grant, Beneficial Ownership, Rule 10b5-1, Surfactants